Capricor Therapeutics, Inc.

Home
United States
San Diego, CA
Capricor Therapeutics, Inc.

Capricor ( ) is a biotechnology company developing transformative therapeutics for diseases.

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dy

strophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.

06/10/2026

Today, Our CEO Linda Marbán presented at the Oppenheimer CNS & NeuroMuscular Summit in Miami, Florida, alongside leaders from Sarepta and Dyne during the “Advancing Duchenne: Perspectives From Industry Leaders” panel. Proud to be part of the important conversations shaping the future of Duchenne muscular dystrophy treatment and innovation.

06/08/2026

Capricor will be participating in two investor conferences this week in Miami — the Goldman Sachs 47th Annual Global Healthcare Conference (fireside chat, June 10 at 10:00 a.m. ET) and the Oppenheimer CNS and Neuro-Muscular Summit.
To view the Goldman Sachs webcast, click here. https://bit.ly/3POYzHT

05/29/2026

We are pleased to welcome Michael Maurer to Capricor as our Chief Commercial Officer. With more than two decades of rare disease commercialization experience across neuromuscular disorders, neuroscience, and immunology, Michael's deep expertise bringing complex therapies to patients further strengthens our team as we prepare for the potential launch of Deramiocel for Duchenne muscular dystrophy and work toward our August 22 PDUFA date. Click here to read the announcement https://bit.ly/3RFEyUw

05/22/2026

Capricor is presenting today at the CureDuchenne FUTURES Conference in Orlando, FL. Join us during the Science Main Stage Session: Preserving, Protecting, & Regenerating Muscle from 11:00 AM – 12:30 PM ET.
View the full conference agenda here: https://web.cvent.com/event/ee9e7402-2c59-420f-9cf9-5731cf20d4d9/websitePage:645d57e4-75eb-4769-b2c0-f201a0bfc6ce

05/14/2026

Capricor is proud to be presenting our HOPE-3 results at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held this week in Boston (May 11–15). With over 2,000 abstracts showcasing the latest in cell and gene therapy, this is one of the premier gatherings in the industry — and we look forward to sharing our data. Click to see the full conference agenda: https://annualmeeting.asgct.org/program-workshops

05/12/2026

Capricor just reported its first quarter 2026 financial results and provided a recent corporate update. Click here to read the full release: https://bit.ly/4udKQcy

05/04/2026

Capricor will report its first quarter 2026 financial results and provide a recent corporate update on May 12 at 4:30 p.m. ET.

Register for the webcast to stay up to date on our progress and key developments: https://bit.ly/3P1v5Ww

04/21/2026

At the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Capricor will be presenting Phase 3 HOPE-3 results for Deramiocel in a late-breaking oral presentation later today. The presentation highlights previously reported topline data demonstrating significant functional benefits in patients with Duchenne muscular dystrophy (DMD). For more information, please click https://bit.ly/4cXjCAt

03/23/2026

Capricor is pleased to be attending the 38th Annual Roth Conference this week in Dana Point, California. The annual conference brings together more than 400 public and private companies, along with investors, for expert-led panels and keynotes across a range of multiple sectors.

03/12/2026

We just reported our fourth quarter and full year 2025 financial results. Click here to read the release: https://bit.ly/4bKdCcP
Our quarterly conference call begins at 4:30 p.m. ET – join the webcast here: https://bit.ly/3NjKRLy

Address

10865 Road To The Cure
San Diego, CA
92121

Website

http://capricor.com/

Alerts

Be the first to know and let us send you an email when Capricor Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Capricor Therapeutics, Inc.:

Shortcuts

Featured

SD Prototypes Manufacturing Solutions, Inc.
8616 Commerce Avenue

Want your business to be the top-listed Engineering Company in San Diego?